<DOC>
	<DOCNO>NCT01566682</DOCNO>
	<brief_summary>The primary Study hypothesis ProLung Test demonstrate safety efficacy risk stratification patient pulmonary lesion identify CT suspicious lung cancer . A statistically significant result indicate patient high ProLung Test result great risk develop lung cancer patient low test result . There three Specific Aims study : 1 . Optimize confirm stability ProLung Test risk-stratification algorithm patient diagnosis . 2 . Externally validate efficacy ProLung Test risk-stratification algorithm compare test result conclusive patient diagnosis . 3 . Assess safety tolerability ProLung Test procedure . Study Design This Study consist two distinct phase , Stabilization Validation . The Study collect data multiple site ( 3 12 ) , site may enroll patient collect data Stabilization Validation Phases minimum three site Validation Phase .</brief_summary>
	<brief_title>A Multi-Center Trial ProLung Testâ„¢</brief_title>
	<detailed_description />
	<mesh_term>Multiple Pulmonary Nodules</mesh_term>
	<mesh_term>Solitary Pulmonary Nodule</mesh_term>
	<criteria>Subjects meet follow criterion may enrol Study : 1 . Subject male female , age 18 old . 2 . Subject undergone CT scan lung ( ) indicate one nodules lesion suspicious lung cancer . 3 . Subject 's pulmonary nodule lesion great 4mm . Size determined large nodule lesion dimension identify CT image . 4 . Subject meet one follow condition : indicate tissue biopsy indicate surgical resection lung 5 . Subject must able receive ProLung Test within 60 day abnormal CT ( Inclusion Criterion 2 &amp; 3 ) within 60 day prior tissue biopsy surgical resection ( Inclusion Criterion 4 ) . 6 . Subject capable understanding agree fulfill requirement Protocol . 7 . Subject sign IRB/IEC approve Informed Consent Form ( `` ICF '' ) . Exclusion Criteria The following criterion disqualify subject enrollment Study : 1 . Subject implanted electronic device chest . 2 . Subject receive therapy suspect chest infection fungal infection tuberculosis . 3 . Subject diagnosed malignancy lung cancer , nonmelanoma skin cancer cancer Principal Investigator suspect metastatic disease lung , 2 suspicious pulmonary nodule . 4 . Subject receive invasive medical surgical procedure within thoracic cavity within 30 day prior ProLung Test within previous 14 day bronchoscopic procedure . 5 . Subject present anomalous physical anatomical condition precludes ProLung Test measurement . 6 . Subject undergone unusually strenuous exercise within 24 hour . 7 . Subject significant systemic disease uncontrolled diabetes , advance heart failure , recent myocardial infarction , medical condition severe morbid obesity judgment Principal Investigator would make him/her unsuitable Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lung Lesion</keyword>
	<keyword>Lung Mass</keyword>
	<keyword>Lung Nodule</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Low-Dose CT</keyword>
	<keyword>CT</keyword>
	<keyword>Diagnostic</keyword>
	<keyword>Evaluation</keyword>
	<keyword>Bioconductance</keyword>
	<keyword>ProLung</keyword>
</DOC>